retatrutide dosing phase 2 trial Guide: 1-12 mg Weekly Triple Agonist (2026) Retatrutide Injection Frequency: Dosing, Safety,

The programme spans multiple trials targeting distinct endpoints: On 21 May 2026 Eli Lilly reported topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial and the programme's first Phase 3 efficacy readout: in 2,339 adults, mean weight loss at the 80-week primary endpoint reached 19.0% (4mg), 25.9% (9mg), and 28.3% (12mg) versus 2.2% for placebo (Eli Lilly investor release

If you have ever tasted a high-quality EVOO and felt that characteristic peppery burn at the back of your throat, you have experienced polyphenols at work -- specifically, one called oleocanthal

Acute improvement of cardiac function with intravenous L-propionylcarnitine in humans

For too long, healthcare systems have waited to treat the consequences of obesity rather than addressing the disease itself